Clinical Trial

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 24, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score \>=10 at baseline.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-06-11; most recent amendment 2025-01-21.
Status change: Recruiting → Active, Not Recruiting 2025-01-21
Status change: Not Yet Recruiting → Recruiting 2021-08-02
Trial Details
NCT Number NCT04430179
Lead Sponsor University of South Florida
Conditions Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Enrollment 30 participants
Start Date 2020-12-17
Primary Completion 2025-07 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2025-01-24